An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.

ABSTRACT:

Background

Estrogen receptor (ER)-negative breast cancer specimens are predominantly of high grade, have frequent p53 mutations, and are broadly divided into HER2-positive and basal subtypes. Although ER-negative disease has overall worse prognosis than does ER-positive breast cancer, not all ER-negative breast cancer patients have poor clinical outcome. Reliable identification of ER-negative tumors that have a good prognosis is not yet possible.

Results

We apply a recently proposed feature selection method in an integrative analysis of three major microarray expression datasets to identify molecular subclasses and prognostic markers in ER-negative breast cancer. We find a subclass of basal tumors, characterized by over-expression of immune response genes, which has a better

SUBMITTER: Teschendorff AE 

PROVIDER: S-EPMC2374988 | biostudies-literature | 2007

REPOSITORIES: biostudies-literature